Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.
Survival of patients treated with venetoclax and decitabine or azacitidine
| Survival | ||||
|---|---|---|---|---|
|
All patients (N = 74) |
Decitabine‐venetoclax (N = 48) |
Azacitidine‐venetoclax (N = 26) |
Significance | |
| Median overall survival—m. | 6.0 m | 8.3 m | 2.6 m | p = 0.080 |
| Progression‐free survival—m. | 4.5 m | 6.1 m | 2.6 m | p = 0.129 |
| Overall survival by ELN 2017 cytogenetic risk category—no. (%) | ||||
| Favorable | 7.6 m | 12.2 m | 1.7 m | p = 0.274 |
| Intermediate | 4.5 m | 5.8 m | 2.1 m | p = 0.031 |
| Adverse | 8.2 m | 8.4 m | 4.0 m | p = 0.439 |
